Syngeneic marrow transplantation in multiple myeloma

Leuk Res. 1992;16(4):415-6. doi: 10.1016/0145-2126(92)90145-w.

Abstract

Two cases of IgA multiple myeloma treated with syngeneic bone marrow transplant and a non-total body irradiation (TBI) conditioning regimen are reported. Both patients presented with stage III disease which responded to standard chemotherapeutic management. The myelo-ablative program for transplant consisted of busulfan and cyclophosphamide (Bu/Cy). Evaluation at 40 days post-transplant revealed no evidence of residual myeloma in either patient. One patient died of disseminated Aspergillus fumigatus at day 73 post-transplant. The other patient relapsed at 18 months post-transplant. This conditioning regimen shows efficacy in aggressive myeloma and could be considered earlier in the disease.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow Transplantation*
  • Busulfan / administration & dosage
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Female
  • Humans
  • Middle Aged
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / radiotherapy
  • Multiple Myeloma / surgery*
  • Transplantation, Isogeneic
  • Whole-Body Irradiation

Substances

  • Cyclophosphamide
  • Busulfan